Publications by authors named "Jean-Louis Labernardiere"

Claim this Profile
P
Pre-Existing Humoral Immunity Enhances Epicutaneously-Administered Allergen Capture by Skin DC and Their Migration to Local Lymph Nodes.
Pierre-Louis Hervé, Camille Plaquet, Noémie Assoun, Nathalie Oreal, Laetitia Gaulme

Front Immunol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epicutaneous immunotherapy protects cashew-sensitized mice from anaphylaxis.
Benjamin Pelletier, Audrey Perrin, Noémie Assoun, Camille Plaquet, Nathalie Oreal

Allergy· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The V protein of Tioman virus is incapable of blocking type I interferon signaling in human cells.
Grégory Caignard, Marianne Lucas-Hourani, Kevin P Dhondt, Jean-Louis Labernardière, Thierry Petit

PLoS One· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measles virus V protein blocks Jak1-mediated phosphorylation of STAT1 to escape IFN-alpha/beta signaling.
Grégory Caignard, Mathilde Guerbois, Jean-Louis Labernardière, Yves Jacob, Louis M Jones

Virology· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo.
Mary Anne Trabaud, Laurent Cotte, Jean Louis Labernardière, Sophie Lebel-Binay, Vinca Icard

J Acquir Immune Defic Syndr· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide.
Africa Holguín, Jean Louis Faudon, Jean-Louis Labernardière, Vincent Soriano

J Clin Virol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
Béatrice Labrosse, Laurence Morand-Joubert, Armelle Goubard, Séverine Rochas, Jean-Louis Labernardière

J Virol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity.
Katharina Skrabal, Sentob Saragosti, Jean-Louis Labernardière, Francis Barin, François Clavel

J Virol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
Eva Poveda, Berta Rodés, Jean-Louis Labernardière, José Miguel Benito, Carlos Toro

J Med Virol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors.
Béatrice Labrosse, Jean-Louis Labernardière, Elisabeth Dam, Virginie Trouplin, Katharina Skrabal

J Virol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis